Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

Secondary outcome evaluations for this clinical study included the following: * To estimate one-year overall survival for research participants with high risk malignancies who receive a haploidentical HSCT * To compare overall survival and cumulative incidence of relapse for the two groups of patients with their corresponding historical controls * To estimate disease-free survival and event-free survival in participants with hematologic malignancies who receive a haploidentical HSCT * To estimate the incidence of overall grade 3-4 acute GvHD in research participants with hematologic malignancies who receive a haploidentical HSCT * To estimate the incidence of chronic GvHD and graft failure in research participants with hematologic malignancies who receive a haploidentical HSCT * To estimate the incidence of non-hematologic regimen-related toxicity and regimen-related mortality in the first 100 days post-transplant in research participants with hematologic malignancies who receive a haploidentical HSCT * To estimate the number of research participants who develop evidence of EBV reactivation or post-transplant lymphoproliferative disease (PTLPD) * To describe disease-free survival, GvHD and engraftment in research participants receiving grafts from Killer immunoglobulin-like receptor (KIR) mismatched and KIR matched haploidentical donors